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Abstract
Background: Ovarian carcinoma is the most important cause of gynecological cancer-related mortality in Western societies.
Despite the improved median overall survival in patients receiving chemotherapy regimens such as paclitaxel and
carboplatin combination, relapse still occurs in most advanced diseased patients. Increased angiogenesis is associated with
rapid recurrence and decreased survival in ovarian cancer. This study was planned to identify an angiogenesis-related gene
expression profile with prognostic value in advanced ovarian carcinoma patients.
Methodology/Principal Findings: RNAs were collected from formalin-fixed paraffin-embedded samples of 61 patients with
III/IV FIGO stage ovarian cancer who underwent surgical cytoreduction and received a carboplatin plus paclitaxel regimen.
Expression levels of 82 angiogenesis related genes were measured by quantitative real-time polymerase chain reaction
using TaqMan low-density arrays. A 34-gene-profile which was able to predict the overall survival of ovarian carcinoma
patients was identified. After a leave-one-out cross validation, the profile distinguished two groups of patients with different
outcomes. Median overall survival and progression-free survival for the high risk group was 28.3 and 15.0 months,
respectively, and was not reached by patients in the low risk group at the end of follow-up. Moreover, the profile
maintained an independent prognostic value in the multivariate analysis. The hazard ratio for death was 2.3 (95% CI, 1.5 to
3.2; p,0.001).
Conclusions/Significance: It is possible to generate a prognostic model for advanced ovarian carcinoma based on
angiogenesis-related genes using formalin-fixed paraffin-embedded samples. The present results are consistent with the
increasing weight of angiogenesis genes in the prognosis of ovarian carcinoma.
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Introduction
Ovarian carcinoma is the most important cause of gynecological
cancer-related mortality in Western societies [1]. This is due to the
fact that approximately 60% of cases are diagnosed at late stages of
disease [2]. While patients with stage I disease have a 5 year
overall survival of 90%, patients with stage III–IV have less than
20% [3,4]. Despite the highly lethal nature of epithelial ovarian
cancer, the clinical course of advanced disease is still difficult to
predict in an individual patient.
Usually, the management of ovarian cancer involves surgery in
order to achieve surgical cytoreduction followed by chemotherapy
[5]. Combination platinum-paclitaxel chemotherapy has become a
standard first line treatment for the advanced-stage disease [6].
Outcome is significantly improved with this regimen, thus 60 to
70% of patients initially respond to platinum-based chemotherapy,
and approximately 40 to 50% achieve complete clinical remission.
However even in this last group, at least half of the patients
experience a recurrence within 4 years [7]. Classical parameters
such as age at diagnosis, extent of disease (as expressed as FIGO
stage), residual disease after surgery, and the histopathological
features of the tumor are important prognostic factors [5].
Nonetheless, these prognostic factors are imperfect predictors of
outcome. This could be due, in part, to the molecular genetic
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that they have yet to be understood. Therefore, a better
understanding of the molecular pathways leading ovarian cancer
is crucial for the establishment of new screening strategies and
more effective therapies. Precise prognostic factors based on gene
expression may identify patients who are more likely to die of
disease despite the achievement reached in response to standard
treatment. Previous studies attempt to develop accurate predictors
of clinical outcome using genome-wide expression arrays. In this
study, we have focused on one of the most important events
involved in carcinogenesis: angiogenesis.
Angiogenesis is a complex and highly regulated process that
consists of the development of new vessels originating from pre-
existing ones. Described first by Judah Folkman in 1971, this
process has been extensively documented as playing a main role in
cancer commencement and progression. Solid tumors must
acquire an angiogenic phenotype to grow beyond a critical size
[8]. This process is regulated by the balance between positive and
negative inputs in the local environment. Regarding ovarian
cancer, increased angiogenesis is associated with rapid recurrence
and decreased survival. Moreover, targeting of Vascular Endothelial
Growth Factor (VEGF) has produced good results in early clinical
trials, thus suggesting the critical role of this process in the
development and maintenance of ovarian carcinomas [9,10].
Although there are many studies on the implication of different
angiogenic factors in ovarian carcinoma, these are not based on
angiogenic profiles related to survival or to treatment response. In
this study, we have evaluated an 82 angiogenesis-related gene set
in a series of 61 advanced ovarian carcinoma samples by
quantitative real-time PCR (qRT-PCR). This technique, consid-
ered the gold standard for measurement of gene expression, has
the ability to analyze very small mRNA fragments makes this assay
feasible for studies with formalin-fixed paraffin-embedded samples,
in which the RNA is moderately or even highly degraded.
The main goal of this study was, therefore, to identify an
angiogenesis-related gene expression profile with prognostic value
in advanced ovarian carcinoma (AOC) patients.
Methods
Patient data
We included 61 non-consecutive FIGO stage III/IV ovarian
carcinomas from patients treated at the Hospital Universitario La Paz
(Madrid, Spain) between February 1996 and December 2003. All
patients underwent a baseline CT scan and exploratory laparotomy
for diagnosis, staging, and debulking when feasible. All patients
received a platinum/taxane-based chemotherapy for at least 6 cycles
in total. Surveillance of patients in the study included periodical
physical examination and CT scan performed three-monthly during
and after the completion of the treatment. Follow-up data were
obtained by retrospective chart review. Approval for the study was
obtained from the Local Ethics Committee (Comite ´E ´tico de
Investigacio ´n Clı ´nica del Hospital Universitario La Paz, ref. PI-
423). According to our Local EthicsC o m m i t t e ei tw a sn o tn e c e s s a r y
to obtain a verbal or written consent for publication from the patients
included in this study considering that this is a retrospective study
based on formalin-fixed, paraffin-embedded tumor samples obtained
between February 1996 and December 2003.
Clinical definitions
Patients were staged according to the International Federation
for Gynecology and Obstetrics (FIGO) classification. Optimal
debulking was defined as #1 cm (diameter) residual disease. A
complete response (CR) was defined as absence of all clinical/
radiographic evidence of disease. In addition, a second-look
laparotomy (SLL) was performed on most of the patients having
achieved a CR after planned treatment, and all of them who were
optimally debulked. In patients that after the treatment planned
achieved a CR and did not accept a SLL, or whether this procedure
was not feasible, and also in patients with a partial response, a
second CT scan was performed one month after the first evaluation
to confirm the response. Progression-free survival (PFS) was defined
as the time interval between the start of the treatment and the first
confirmed sign of disease recurrence or progression. Overall
survival (OS) was defined as the time interval between the start of
the treatment and the date of death or end of follow-up.
RNA extraction and reverse transcription
To determine the gene expression patterns in tumor biopsies,
tissue sections previously stained with hematoxylin and eosin were
reviewed by an experienced pathologist. Eligible samples included
at least 80% of tumor cells and no large necrotic areas. Four to
eight 4-mm sections were used for RNA isolation, with the
Masterpure RNA Purification Kit (EPICENTRE Biotechnologies,
Madison, WI, USA) according to the manufacturer’s instructions.
One mg of total RNA was used for cDNA synthesis according to
the protocol provided with the High Capacity cDNA Reverse
Transcription kit (Applied Biosystems, Foster City, CA, USA).
Gene selection and qRT-PCR
The selection of genes included in the study was as follows: first, we
selected genes previously described in ovarian carcinoma samples or
cell lines with a role in the carcinogenesis process. Second, we also
included genes described asmodulatorsofangiogenic process,butnot
previously described in ovarian carcinoma. Thus, eighty two genes
were selected by literature data mining. Specific TaqMan Gene
Expression assays for each gene were selected and gene expression
was determined by qRT-PCR with TaqMan Low Density Arrays
(TLDA) in an ABI PRISM 7900 HT Sequence Detection System
(Applied Biosystems). Each TLDA was configured with 96 genes by
duplicate for two samples. Fourteen housekeeping genes selected by
GeNorm Analysis software, as previously described [11], were added
to normalize the raw data.
Ct values, defined as the point at which the fluorescence rises
above the background fluorescence [12], were calculated with
SDS 2.2 software (Applied Biosystems). We applied a normaliza-
tion factor based on the geometric mean of the best-performing
housekeeping genes.
Statistical Analysis
Quantitative data were described by median (minimun-max-
imun) and qualitative data as absolute frequencies and percentages.
Associations between categorical variables were evaluated with the
x
2 test and the Fischer’s exact test when appropriate. All deaths
observed in the data set were cancer related, meaning that OS is
equivalent to cancer-specific survival for purposes of this analysis.
OS and PFS curves were generated by the Kaplan-Meier method,
and differences between survival curves were assessed for statistical
significance with the log-rank test.
The Cox regression analysis was used to build multiple models
based on the combination of significant genes. The Akaike
Information Criterion based selection was used to find the most
accurate one [13]. Protective genes were defined as those
associated with a hazard ratio (HR) of less than 1; risk genes
were defined as those associated with a hazard ratio of more than
1. Two risk groups (low and high risk) were then assigned
according to the expression level of the genes included in the
profile.
Angiogenesis in Ovarian Cancer
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the estimated accuracy of the gene profile could be over-
optimized. To correct this bias, we performed a leave-one-out
cross validation (LOOCV) [14]. The model accuracy was
determined by using the receiver operating characteristics
(ROC) curves to calculate its sensitivity and specificity. The
Kaplan-Meier method coupled to a log-rank test was used to
generate survival curves. Multivariate analysis for confounding
factors was carried out by using Cox proportional hazards
regression with categorical or continuous variables as appropriate.
For this analysis, gene profile was considered a binary category
(low risk or high risk). P values of all statistics tests were two sided.
SAS 9.1, Enterprise Guide 3.0 and SPSS (version 9.0; SPSS Inc
Chicago, IL, USA) packages were used for statistical tests.
LOOCV was performed using R language version 2.2 with the
Design Software package version 2.0.
Results
The median age at diagnosis was 53 years (range, 21 to
82 years). All patients had advanced disease (FIGO stages III/IV).
Most of them had FIGO stage III (51, 83.6%), grade 3 tumors (35,
57.4%), and serous histology (42, 68.9%). Thirty one percent of
patients were optimally cytoreduced after initial surgery (#1c m
residual diameter disease). All received postoperative taxane-
platinum based combination therapy and 52 patients (85.2%)
achieved an initial response to this therapy. The median follow-up
was 44 months (range, 1 to 127 months), with a median OS of
40 months (95% CI 25.4–54.8) and a median PFS of 17 months
(95% CI 13.7–20.6) for the entire group.
Optimal surgery and response to initial treatment were
predictors of survival in the univariate analysis. None of the other
clinico-pathological characteristics (FIGO stage, age and histopa-
thology) showed statistically significance in the univariate analysis
(Table 1).
Gene expression analysis and the development of the
prognostic profile
In order to evaluate reference gene stability among samples, Ct
values of 14 housekeeping genes were imported into GeNorm
v.3.4 [11]. This software was developed to identify which ones and
how many control genes should be used from a larger list of
putative ones, based on the lowest variation among samples. With
this approach, we obtained a combination of five genes (18S,
ACTB, B2M, GAPDH and GUSB) which was the most appropriated
to normalize the results. The remaining 9 genes (HMBS, HPRT1,
IPO8, PGK1, PPIA, RPLP0, TBP, TFRC and UBC) were excluded
from the study because of the high variability between samples.
We calculated a normalization factor based on the geometric
mean of those genes, and we applied it to expression values of all
the other genes tested.
Hazard ratios from univariate Cox regression analysis were used
to determine which genes were associated with OS. The approach
to model building for prediction in survival analysis was based on
the combination of stepwise regression, Akaike information criteria
(AIC), and the best subset selection: Stepwise-AIC-Best Subsets
approach. As all the samples were used to generate the model,
LOOCV was applied to avoid bias related to the accuracy
overestimation of the model.
We established a 34 gene profile related to OS of ovarian
carcinoma patients (Table S1). Hazard ratios from the univariate
Cox regression analysis showed that the levels of expression of 34
genes correlated with OS: 17 were protective genes (hazard ratio
less than 1) and 17 were risk genes (hazard ratio of more than 1).
With this profile, we were able to distinguish between two groups
of patients (low risk and high risk) with a sensitivity of 87.2% and a
specificity of 86.4% after LOOCV. According to this classification,
the high-risk group had a median OS of 28.3 months (95% CI,
22.8 to 33.8) (p,0.0001) whereas median OS was not reached in
the low risk group at the end of follow-up (HR: 2.72, 95% CI:
1.85–4.00, p,0.0001) (Figure 1A and B).
The prognostic profile was also used to asses PFS (Figures 1C
and D). Median PFS for the high risk group was 15.0 months
(95% CI, 12.5 to 17.6) (p,0.0001) and was not reached in the low
risk group (HR: 1.03, 95% CI, 1.02–1.04, p,0.001).
Figure 2 shows the Kaplan-Meier analysis as a function of gene
profile for homogeneous subsets of patients. Our profile main-
tained its significance even in the group of responders. Thus, the
analysis amongst patients who achieved a partial or complete
response showed a median OS for the high risk group of
33.3 months (95% CI, 27.8 to 38.9) whereas it was not reached for
the low risk group (p,0.0001). Therefore, the profile provided
excellent discrimination of survival curves for these patients’
subsets.
The univariate analysis showed a statistically significant
association between the angiogenesis-related gene expression
profile and the debulking status and the response to treatment
(complete or partial response vs absence of response) (Table 2).
Table 1. Univariate and multivariate analysis for PFS and OS.
Univariate p & HR (95% CI) values Multivariate p & HR (95% CI) values
PFS OS PFS OS
Debulking status (,1c mv s$1 cm) 0.023 0.45 (0.23–0.91) 0.003 0.27 (0.12–0.63) 0.547 0.79 (0.36–1.71) 0.625 0.75 (0.23–2.37)
Age (#40 vs .40) 0.395 N/A 0.556 N/A N/A N/A N/A N/A
Stage (III vs IV) 0.985 N/A 0.867 N/A N/A N/A N/A N/A
Histology (serous vs other) 0.339 N/A 0.807 N/A N/A N/A N/A N/A
Grade (1 vs 2–3) 0.148 N/A 0.338 N/A N/A N/A N/A N/A
Profile (low vs high risk) ,0.001 1.03 (1.02–1.04) ,0.001 2.72 (1.85–4.00) ,0.001 1.03 (1.02–1.04) ,0.001 2.25 (1.58–3.20)
Response to treatment (complete
plus partial vs absence)
,0.001 0.24 (0.11–0.51) ,0.001 0.08 (0.03–0.19) 0.497 0.76 (0.35–1.67) 0.041 0.054 (0.03–0.889)
P, hazard ratio (HR) and 95% confidence interval (95% CI) values from unadjusted and adjusted Cox Regression. Hazard ratios for non significant values are noted as N/A.
doi:10.1371/journal.pone.0004051.t001
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The prognostic profile maintained independent prognostic
significance in multivariate analysis when correcting for debulking
status and the response to therapy. The HR for death in low risk
group versus the high risk group was 2.25 (95% CI, 1.58 to 3.20;
p,0.001) (Table 1). Debulking status was not independently
associated with OS, and the achievement of a response had a HR
of 0.054 (95% CI, 0.03 to 0.889, p=0.041). The results were
similar when related to the PFS, with a HR for the prognostic
profile of 1.03 (95% CI, 1.02 to 1.04; p,0.001). In this setting,
neither the debulking status nor the responses were independent
prognostic factors.
Discussion
Microarray technologies have already provided valuable
expression data in the classification of ovarian cancers based on
gene profiling [15–19]. However, the selection of patients for new
therapeutic strategies remains a challenge [20,21].
Low density arrays combine the capacity to measure the
expression of many genes in a single sample (such as microarrays
approach), while retaining the sensitivity and quantitative range
offered by qRT-PCR.
An important limitation of high throughput techniques is the
high quality requirements of starting RNA. The improvement of
isolating RNA kits and the intrinsic characteristics of the qRT-
PCR approach has overcome the problem of using formalin-fixed,
paraffin-embedded samples. The ability of real-time RT-PCR to
test the expression of very small mRNA fragments makes this assay
affordable for studies with these kind of samples, in which the
RNA is moderately or even highly degraded, and yet it still
produces reliable results [22,23]. Moreover, RT-PCR may be
more feasible in the clinical setting than microarray-based
technologies due to the need for specialized laboratory facilities
and complex statistical analysis [15–19].
We tried to obtain the maximum biological plausibility
analyzing the expression of a group of genes involved in the same
biological process by studying pathways implicated in the
Figure 1. Kaplan-Meier OS curve of low risk versus high risk group (A). Kaplan-Meier curve after LOOCV (B). Kaplan-Meier PFS curve of low
risk against high risk (C). Kaplan-Meier curve after LOOCV (D).
doi:10.1371/journal.pone.0004051.g001
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RNA was extracted from 61 samples. We used Cox regression
analysis based on the combination of significant genes for model
selection. The Akaike Information Criterion was used to find the
most accurate one [13]. Rather than splitting data into test and
validation sets, we performed a cross-validation, that uses repeated
data-splitting to prevent model overfitting and to generate
accurate estimates of model coefficients, being a compelling
statistical technique for model validation [14].
In the present study, the angiogenesis-related gene profile
provided independent prognostic information for OS outcome in
patients with advanced epithelial ovarian cancer. In addition, the
profile allowed the differentiation of two groups with different PFS
outcome (Figure 1).
The prognostic power of the angiogenesis profile was indepen-
dent on its association with the debulking status, which is the best
established prognostic factor in advanced ovarian carcinoma.
Moreover the profile was the only variable that achieved
prognostic significance in both the OS and PFS multivariate
analysis in our study (Table 1). Even though there was an
association between response to treatment and the profile
(p=0.007), the profile maintained a strong prognostic significance
when applied to the homogeneous group of patients with
chemosensitive disease, thus confirming its independent value.
This prognostic profile may have important clinical implications,
as a tool to complement clinical risk-stratification of ovarian
carcinoma patients.
Many of the genes included in the prognostic profile are known
to confer a poor outcome for patients with advanced epithelial
ovarian cancer (Table S1). One of these genes is the VEGF. Several
in vitro studies showed that VEGF is crucially involved in various
Figure 2. Kaplan-Meier OS curve (low risk versus high risk) in
optimally debulked subgroup (A), in FIGO stage III subgroup
(B), and in differentiation grade 3 subgroup (C).
doi:10.1371/journal.pone.0004051.g002
Table 2. Relationship between the angiogenesis-related
gene profile and clinico-pathological parameters.
Low risk group High risk group p
Nr % Nr %
Age
#40 2 3.3 5 8.2 0.694
.40 22 36.0 32 52.5
Grade
1 3 5.0 2 3.3 0.380
2–3 21 35.0 34 56.7
Stage
III 19 31.2 32 52.4 0.495
IV 5 8.2 5 8.2
Histology
Serous 17 27.9 25 41.0 0.788
Other histology 7 11.5 12 19.6
Debulking status
Optimal 12 25.5 7 14.9 0.019
Suboptimal 8 17.0 20 42.6
Response
Yes 24 39.3 28 45.9 0.007
No 0 0 9 14.8
P values: x
2 for histology and debulking status, Fischer’s exact test for stage,
grade and age.
doi:10.1371/journal.pone.0004051.t002
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histochemically detected VEGF overexpression and elevated
serum levels of VEGF were shown to be associated with an
impaired prognosis [26–29]. As expected, wild-type BRCA2 was a
risk gene. It is well known that BRCA deficient cells are particularly
sensitive to platinum compounds [30,31]. PDGFRa has been linked
to poor prognosis and aggressive tumor characteristics [32,33].
Furthermore, a previous report showed that the presence of this
receptor at the mRNA level suggested that an autocrine or
paracrine loop might be functional in epithelial ovarian cancer
[34]. Moreover, PDGFRa was a component of the molecular
profile reported by Spentzos et al [15]. Recently, ID1 up-
regulation was correlated with poor prognosis [35]. Thus, the
presence of this gene in our profile underlined the importance of
this family of proteins involved in angiogenesis.
Our profile also included some genes that are well known for
their involvement in angiogenesis but, otherwise, their implication
in prognosis of AOC has not been yet well established. Amongst
them, EPHB2 has only been reported twice as a biomarker with
negative prognostic value in ovarian carcinoma [15,36]. One of
the matrix metalloproteinases inhibitor family involved in the
epithelial to the mesenchymal transition, TIMP1, emerged in our
profile as a protective factor. The presence of EPOR as a risk factor
is another pathway to be explored in further studies. A recent
study has described a paracrine mechanism of growth related to
EPOR/EPO interaction, apparently independent of exogenous
EPO [37]. These interesting observations about the role of these
genes in ovarian cancer remain to be undoubtedly established and
cannot be conclusively derived from this descriptive study.
An important advantage of our profile is that it has been
developed from formalin-fixed, paraffin embedded tissue thus
allowing its use in a widespread clinical setting without the need of
frozen tumor tissue, which is usually only available in tertiary
referral hospitals or research centers that have frozen tissue banks.
Although our series is quite homogeneous, the fact that our study
analyzed a relatively small number of samples may seem a
limitation. Notwithstanding the majority of the profiling studies
previously published on ovarian cancer used a similar number of
cases [16,38].
Our profile could be used as prognostic tool to enable clinicians
to identify those high risk patients who will potentially benefit from
alternative drug combinations. Moreover, due to the successful
introduction of the antiangiogenic drugs in resistant advanced
epithelial ovarian cancer, we could consider patients with a high
risk to benefit from a combination of platinum-taxane chemo-
therapy with a novel antiangiogenic drug. Nevertheless, although
our data suggest the potential utility of this approach, the
prognostic value of our qRT-PCR based angiogenesis-related
gene expression profile should be further evaluated in prospective
studies of patients with advanced epithelial ovarian cancer.
Supporting Information
Table S1 Profile genes associated with overall survival.
Found at: doi:10.1371/journal.pone.0004051.s001 (0.06 MB
DOC)
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